Crystalline forms of (S)-2-(7-Cyano-1H-benzimidazol-1 yl)- N-{1-(4-(1-cyano-1-methylethyl)phenyl)ethyl}acetamide

Crystalline Forms of a compound of Formula I are provided. Crystalline Form A is among the crystalline Forms identified. Form A has an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2Θ (+0.2° 2Θ) at 3.07, 5.96, 11.89 and 17.85, and a Differential Scanning Ca...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	JIANG, Jilong, TSE, Alan
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TESTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Crystalline Forms of a compound of Formula I are provided. Crystalline Form A is among the crystalline Forms identified. Form A has an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2Θ (+0.2° 2Θ) at 3.07, 5.96, 11.89 and 17.85, and a Differential Scanning Calorimetry (DSC) thermogram that exhibits an endotherm having a peak temperature of about 168.9°C. Crystalline Form A is useful as a pharmaceutical composition and can be used as an antagonist of VR1. It may be used in the treatment of nociceptive pain disorders.